Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Sep;72(3):490-9.
doi: 10.1111/j.1365-2125.2011.03995.x.

Additional safety risk to exceptionally approved drugs in Europe?

Arna H Arnardottir  1 , Flora M Haaijer-Ruskamp, Sabine M J Straus, Hans-Georg Eichler, Pieter A de Graeff, Peter G M Mol
Affiliations

Additional safety risk to exceptionally approved drugs in Europe?

Arna H Arnardottir et al. Br J Clin Pharmacol. 2011 Sep.

Abstract

Aims: Regulatory requirements for new drugs have increased. Special approval procedures with priority assessment are possible for drugs with clear 'unmet medical need'. We question whether these Exceptional Circumstances (EC) or Conditional Approval (CA) procedures have led to a higher probability of serious safety issues.

Methods: A retrospective cohort study was performed of new drugs approved in Europe between 1999 and 2009. The determinant was EC/CA vs. standard procedure approval. Outcome variables were frequency and timing of a first Direct Healthcare Professional Communication (DHPC). An association between approval procedure and the time from market approval to DHPC was assessed using Kaplan-Meyer survival analysis and Cox-regression to correct for covariates.

Results: In total 289 new drugs were approved. Forty-six (16.4%) were approved under EC or CA, of which seven received a DHPC (15%). This was similar to the standard approval drugs (243), of which 33 received one or more DHPC (14%, P= 0.77). The probability of acquiring a DHPC for standard approval drugs vs. EC/CA drugs during 11-year follow-up is 22% (95% CI 14%, 29%) and 26% (95% CI 8%, 44%), respectively (log-rank P= 0.726). This difference remained not significant in the Cox-regression model: hazard ratio 0.94 (95% CI 0.40, 2.20). Only drug type was identified as a confounding covariate.

Conclusion: The EC/CA procedure is not associated with a higher probability of DHPCs despite limited clinical development data. These data do not support the view that early drug approval increases the risk of serious safety issues emerging after market approval.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Proportion of new active substances (NAS) that obtained a marketing authorization between 1999 and 2009 under exceptional circumstances/conditional approval (EC/CA) or standard marketing authorizations with or without a Direct Healthcare Provider Communication (DHPC)
Figure 2
Figure 2
Proportion of new active substances authorized under exceptional circumstances/conditional approval (EC/CA) or standard conditions with a subsequent Direct Healthcare Provider Communication (DHPC)
See this image and copyright information in PMC

References

    1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200–5. - PubMed
    1. Leendertse AJ, Egberts AC, Stoker LJ, van den Bemt PM, HARM Study Group Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med. 2008;168:1890–6. - PubMed
    1. Califf RM, CERTs Benefit Assessment Workshop Participants Benefit assessment of therapeutic products: the Centers for Education and Research on Therapeutics. Pharmacoepidemiol Drug Saf. 2007;16:5–16. - PubMed
    1. Wieringa NF, Peschar JL, Denig P, de Graeff PA, Vos R. Connecting pre-marketing clinical research and medical practice: opinion-based study of core issues and possible changes in drug regulation. Int J Technol Assess Health Care. 2003;19:202–19. - PubMed
    1. Eichler HG, Pignatti F, Flamion B, Leufkens H, Breckenridge A. Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma. Nat Rev Drug Discov. 2008;7:818–26. - PubMed

Substances

LinkOut - more resources